Entest BioMedical's Subsidiary Zander Therapeutics, Inc. Reports on Preliminary Canine Experiments Testing New Anti-Inflammatory Drug Compounds
Entest BioMedical Inc.'s (PINK: ENTB) subsidiary, Zander Therapeutics Inc. ,reported that initial data from its canine study suggest that compounds currently being tested ex vivo show promise as small molecule anti-inflammatory treatments in canines. The Company is in the process of developing anti-cancer and anti-inflammatory drugs for the Canine, Feline and Equine markets. David Koos, CEO of both Entest BioMedical and Zander, stated "Finding that compounds being developed by Regen BioPharma, Inc. for modulating NR2F6 in humans appear to modulate NR2F6 in dogs is an extremely exciting development. There can be a direct crossover effect in drug development."
Zander Therapeutics :: Specializing in cutting edge therapies for animals
Founded in 2015 as a biotechnology company focused on veterinary medicine, specifically small molecule treatments for veterinary cancers, autoimmune diseases such as arthritis and other immunotherapies for specialty niche treatments. Zander is wholly owned by Entest BioMedical Inc. a fully reporting and trades publicly under the symbol: ENTB Focused on immuno-oncology, stem cell/cancer stem cell, gene silencing.
Copyright Zander Therapeutics, Inc. 2017